-
Article
Open AccessThe pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma
Despite the advent of neoadjuvant chemoradiotherapy (CRT), overall survival rates of esophageal adenocarcinoma (EAC) remain low. A readily induced mesenchymal transition of EAC cells contributes to resistance ...
-
Article
Open AccessPersister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to chemotherapy remain a significant clinica...
-
Article
Open AccessDriver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression
The molecular basis of disease progression from UV-induced precancerous actinic keratosis (AK) to malignant invasive cutaneous squamous cell carcinoma (cSCC) and potentially lethal metastatic disease remains u...
-
Article
Open AccessAuthor Correction: Genomic basis for RNA alterations in cancer
-
Article
Open AccessLoss of FGFR4 promotes the malignant phenotype of PDAC
Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours. Here, we aimed to clarify the role of FGFR1 and F...
-
Article
Open AccessCDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intri...
-
Chapter
Gone Rogue: Re-wilding Education in Alternative Outdoor Learning Environments
Humans have relied on an intimate relationship with nature for their personal growth, holistic development and ongoing survival. As practitioner-researchers and teacher-educators, the authors have developed a ...
-
Article
Open AccessDNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association
Here we report the DNA methylation profile of 84 sporadic pancreatic neuroendocrine tumors (PanNETs) with associated clinical and genomic information. We identified three subgroups of PanNETs, termed T1, T2 an...
-
Article
Open AccessGenomic basis for RNA alterations in cancer
Transcript alterations often result from somatic changes in cancer genomes1. Various forms of RNA alterations have been described in cancer, including overexpression2, altered splicing3 and gene fusions4; however...
-
Chapter
PDAC Subtypes/Stratification
Large-scale sequencing analyses have transformed our understanding of PDAC and have defined several molecular taxonomies that now guide pre-clinical and clinical therapeutic development. The identification of ...
-
Article
Molecular subtypes of pancreatic cancer
Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences ...
-
Article
Open AccessMutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels
Mutant p53s (mutp53) increase cancer invasiveness by upregulating Rab-coupling protein (RCP) and diacylglycerol kinase-α (DGKα)-dependent endosomal recycling. Here we report that mutp53-expressing tumour cells...
-
Article
Correction: Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours
Nature 543, 65–71 (2017); doi:10.1038/nature21063 It has been brought to our attention that in Fig. 2d of this Article, an incorrect Sanger trace was used to represent the breakpoint of the EWSR1 and FLI1 type...
-
Article
Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
Michael Schatz, David Tuveson and colleagues analyze somatic noncoding alterations in 308 pancreatic ductal adenocarcinomas. They find recurrent noncoding regulatory mutations that correlate with differential ...
-
Article
Open AccessBRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
Pancreatic cancer has become the third leading cause of cancer death with minimal improvements in outcome for over 40 years. Recent trials of therapies that target-defective DNA maintenance using poly (ADP-rib...
-
Article
Whole-genome landscape of pancreatic neuroendocrine tumours
The diagnosis of pancreatic neuroendocrine tumours (PanNETs) is increasing owing to more sensitive detection methods, and this increase is creating challenges for clinical management. We performed whole-genome...
-
Article
Open AccessAn integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by K...
-
Article
Open AccessExploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenviro...
-
Article
Genomic analyses identify molecular subtypes of pancreatic cancer
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SN...
-
Article
Whole genomes redefine the mutational landscape of pancreatic cancer
Pancreatic cancer remains one of the most lethal of malignancies and a major health burden. We performed whole-genome sequencing and copy number variation (CNV) analysis of 100 pancreatic ductal adenocarcinoma...
